RVLPQ Projected Dividend Yield
Ord/RVL Pharmaceuticals plc ( OTCBB : RVLPQ )RVL Pharmaceuticals plc is a specialty pharmaceutical company. Co. is focused on the commercialization of UPNEEQ, or RVL-1201 (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. It is focused on growing Upneeq with eye care and medical aesthetic professionals and providing a prescription experience for patients through its pharmacy. RVL Pharmacy dispenses Upneeq only. Co. is also developing Arbaclofen ER tablets for the alleviation of spasticity in multiple sclerosis patients. Its target patient population comprises adults with droopy or low-lying eyelids or acquired ptosis, the majority of whom are female. 21 YEAR PERFORMANCE RESULTS |
RVLPQ Dividend History Detail RVLPQ Dividend News RVLPQ Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |